The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

被引:1402
作者
Pertwee, R. G. [1 ]
机构
[1] Univ Aberdeen, Sch Med Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland
关键词
D O I
10.1038/sj.bjp.0707442
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (-)-trans-Delta(9)-tetrahydrocannabinol(Delta(9)-THC), (-)-cannabidiol (CBD) and (-)-trans-Delta(9)-tetrahydrocannabivarin (Delta(9)-THCV), interact with cannabinoid CB1 and CB2 receptors. Delta(9)-THC, the main psychotropic constituent of cannabis, is a CB1 and CB2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by the expression level and signalling efficiency of cannabinoid receptors and by ongoing endogenous cannabinoid release. CBD displays unexpectedly high potency as an antagonist of CB1/CB2 receptor agonists in CB1- and CB2-expressing cells or tissues, the manner with which it interacts with CB2 receptors providing a possible explanation for its ability to inhibit evoked immune cell migration. Delta(9)-THCV behaves as a potent CB2 receptor partial agonist in vitro. In contrast, it antagonizes cannabinoid receptor agonists in CB1-expressing tissues. This it does with relatively high potency and in a manner that is both tissue and ligand dependent. Delta(9)-THCV also interacts with CB1 receptors when administered in vivo, behaving either as a CB1 antagonist or, at higher doses, as a CB1 receptor agonist. Brief mention is also made in this review, first of the production by Delta(9)-THC of pharmacodynamic tolerance, second of current knowledge about the extent to which Delta(9)-THC, CBD and Delta(9)-THCV interact with pharmacological targets other than CB1 or CB2 receptors, and third of actual and potential therapeutic applications for each of these cannabinoids.
引用
收藏
页码:199 / 215
页数:17
相关论文
共 185 条
[1]   Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis [J].
Aguado, Tania ;
Carracedo, Arkaitz ;
Julien, Boris ;
Velasco, Guillermo ;
Milman, Garry ;
Mechoulam, Raphael ;
Alvarez, Luis ;
Guzman, Manuel ;
Galve-Roperh, Ismael .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (09) :6854-6862
[2]   Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist [J].
Amaya, Fumimasa ;
Shimosato, Goshun ;
Kawasaki, Yasuhiko ;
Hashimoto, Satoru ;
Tanaka, Yoshifumi ;
Ji, Ru-Rong ;
Tanaka, Masaki .
PAIN, 2006, 124 (1-2) :175-183
[3]   Direct inhibition by cannabinoids of human 5-HT3A receptors:: probable involvement of an allosteric modulatory site [J].
Barann, M ;
Molderings, G ;
Brüss, M ;
Bönisch, H ;
Urban, BW ;
Göthert, M .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (05) :589-596
[4]   (-)-Delta(9)-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase [J].
Bayewitch, M ;
Rhee, RH ;
AvidorReiss, T ;
Breuer, A ;
Mechoulam, R ;
Vogel, Z .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (17) :9902-9905
[5]   CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms [J].
Beltramo, M ;
Bernardini, N ;
Bertorelli, R ;
Campanella, M ;
Nicolussi, E ;
Fredduzzi, S ;
Reggiani, A .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 23 (06) :1530-1538
[6]   Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol [J].
Berrendero, F ;
Maldonado, R .
PSYCHOPHARMACOLOGY, 2002, 163 (01) :111-117
[7]   Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis [J].
Berrendero, F ;
Sánchez, A ;
Cabranes, A ;
Puerta, C ;
Ramos, JA ;
García-Merino, A ;
Fernández-Ruiz, J .
SYNAPSE, 2001, 41 (03) :195-202
[8]  
Bifulco M, 2007, ONCOL REP, V17, P813
[9]   Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide [J].
Bisogno, T ;
Hanus, L ;
De Petrocellis, L ;
Tchilibon, S ;
Ponde, DE ;
Brandi, I ;
Moriello, AS ;
Davis, JB ;
Mechoulam, R ;
Di Marzo, V .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (04) :845-852
[10]   Cannabinoid receptors as novel targets for the treatment of melanoma [J].
Blazquez, Cristina ;
Carracedo, Arkaitz ;
Barrado, Lucia ;
Jose Real, Pedro ;
Fernandez-Luna, Jose Luis ;
Velasco, Guillermo ;
Malumbres, Marcos ;
Guzman, Manuel .
FASEB JOURNAL, 2006, 20 (14) :2633-+